Several classes of antihypertensive agents have been in clinical use, including diuretics, α-
blockers, β-blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II type 1 …

Hypertension is one of the most common conditions seen in primary care and a major public
health problem in India. It can lead to various complications if not detected early and treated …

Cilnidipine (FRC-8653) is a dihydropyridine (DHP) type of calcium channel antagonist
originally developed in Japan. Unlike other calcium channel antagonists, cilnidipine blocks …

Hypertension is one of the major risk factors for coronary heart disease and the most
important risk factor for cerebrovascular diseases (1). In most countries, almost 20% of the …

The second half of the 20th century has seen a constant de-crease in cardiovascular
mortality in the Western industrialised nations [1]. This decrease has occurred concomitantly …

Cilnidipine is a novel and unique 1, 4-dydropyridine derivative calcium antagonist that
exerts potent inhibitory actions not only on L-type but also on N-type voltage-dependent …

Calcium antagonists comprise the most popular drug class for treatment of hypertension in
Japan. More than half of Japanese clinicians use calcium antagonists as initial drug …

Cilnidipine is a unique Ca2+ channel blocker with an inhibitory action on the sympathetic N‐
type Ca2+ channels, which is used for patients with hypertension in Japan. Cilnidipine has …

Calcium channel blockers (CCBs), particularly dihydropyridine-CCBs,(DHP-CCBs), have an
established role in antihypertensive therapy, either as monotherapy or in combination with …

Multiple studies have demonstrated dihydropyridine calcium‐channel blocker (CCB) therapy
to be appropriate for the treatment of hypertension, as is reflected in treatment guidelines …